New ViiV HIV-1 Treatments get Clearance from UK MHRA

Two novel cabotegravir compositions from ViiV Healthcare have been accepted by MHRA, providing a new method of HIV-1 prophylaxis. 

 The medications that have been authorised for use as prophylactics prior to exposure are Apretude 30 mg film-coated tablets and Apretude 600 mg long term solution for injections. 

 
 
Cabotegravir is recommended for use for young people that weigh at least 35 kg as well as adults that are more susceptible to HIV-1 infection. It has been cleared for use as tablets and as a persisting injectable.

 The first injectable medication for HIV avoidance licenced in the UK is the 600 mg long-lasting injection, which is given on an ongoing basis. One injection every two months after the first two being in one month after another are administered under this schedule.

Before using cabotegravir, individuals must have an HIV test with a negative result.